Quality Indicators for the Management of Heart Failure in Vulnerable Elders
Authors: Gregg C. Fonarow
Journal: Annals of Internal Medicine (2001)

Quality Indicators for Assessing Care of Vulnerable Elders16 October 2001Quality Indicators for the Management of Heart Failure in Vulnerable EldersGregg C. Fonarow, MDGregg C. Fonarow, MDFrom University of California, Los Angeles, Los Angeles, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-8_Part_2-200110161-00008 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Heart failure is a common medical condition that contributes to substantial morbidity and mortality in elderly persons and greatly affects public health. In the United States, an estimated 4.6 million persons have heart failure, and 400 000 to 700 000 new cases develop each year (1). The prevalence of heart failure increases with age: It is present in 2% of persons 40 to 59 years of age, more than 5% of persons 60 to 69 years of age, and 10% of persons 70 years of age or older. As the U.S. population ages, the incidence and prevalence of this disease ...References 1. American Heart Association. Heart and Stroke Statistical Update. Dallas, TX: American Heart Assoc; 1997. Google Scholar 2. Shekelle PG, MacLean CH, Morton SC, Wenger NS. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med. 2001;135:647-52. LinkGoogle Scholar 3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-91. [PMID: 1463530] CrossrefMedlineGoogle Scholar 4. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al ; The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-77. [PMID: 1386652] CrossrefMedlineGoogle Scholar 5. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al ; Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-6. [PMID: 7477219] CrossrefMedlineGoogle Scholar 6. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53. [PMID: 10639539] CrossrefMedlineGoogle Scholar 7. Garg R, Yusuf S; Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-6. [PMID: 7654275] CrossrefMedlineGoogle Scholar 8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35. [PMID: 2883575] CrossrefMedlineGoogle Scholar 9. Gambassi G, Lapane KL, Sgadari A, Carbonin P, Gatsonis C, Lipsitz LA, et al . Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch Intern Med. 2000;160:53-60. [PMID: 10632305] CrossrefMedlineGoogle Scholar 10. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al . Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-52. [PMID: 9074572] CrossrefMedlineGoogle Scholar 11. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al . Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7. [PMID: 10821361] CrossrefMedlineGoogle Scholar 12. Kahn KL, Rogers WH, Rubenstein LV, Sherwood MJ, Reinisch EJ, Keeler EB, et al . Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system. JAMA. 1990;264:1969-73. [PMID: 2120476] CrossrefMedlineGoogle Scholar 13. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282-9. [PMID: 9462531] CrossrefMedlineGoogle Scholar 14. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med. 1996;125:304-10. [PMID: 8678395] LinkGoogle Scholar 15. Philbin EF, Garg R, Danisa K, Denny M, Gosselin G, Hassapoyannes C, et al ; Digitalis Investigation Group. The relationship between cardiothoracic ratio and left ventricular ejection fraction in congestive heart failure. Arch Intern Med. 1998;158:501-6. [PMID: 9508228] CrossrefMedlineGoogle Scholar 16. Dei Cas L, Metra M, Leier CV. Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects. Clin Cardiol. 1995;18:370-6. [PMID: 7554541] CrossrefMedlineGoogle Scholar 17. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med. 1988;148:2013-6. [PMID: 3046541] CrossrefMedlineGoogle Scholar 18. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190-5. [PMID: 7565975] CrossrefMedlineGoogle Scholar 19. Senni M, Rodeheffer RJ, Tribouilloy CM, Evans JM, Jacobsen SJ, Bailey KR, et al . Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol. 1999;33:164-70. [PMID: 9935024] CrossrefMedlineGoogle Scholar 20. Konstam, Marvin A. Heart Failure: Management of Patients with Left-Ventricular Systolic Dysfunction. Quick Reference Guide for Clinicians. Clinical Practice Guideline No. 11. Rockville, MD: U.S. Department of Health and Human Services; 1994. AHCPR publication no. 94-0612. Google Scholar 21. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of β-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized, controlled trials. Eur Heart J. 1997;18:560-5. [PMID: 9129883] CrossrefMedlineGoogle Scholar 22. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-91. [PMID: 9743509] CrossrefMedlineGoogle Scholar 23. Heidenreich PA, Lee TT, Massie BM. Effect of β-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27-34. [PMID: 9207617] CrossrefMedlineGoogle Scholar 24. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al ; U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-55. [PMID: 8614419] CrossrefMedlineGoogle Scholar 25. . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13. [PMID: 10023943] CrossrefMedlineGoogle Scholar 26. . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7. [PMID: 10376614] CrossrefMedlineGoogle Scholar 27. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al . Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-58. [PMID: 11386263] CrossrefMedlineGoogle Scholar 28. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-61. [PMID: 2242521] CrossrefMedlineGoogle Scholar 29. Ryman KS, Kubo SH, Lystash J, Stone G, Cody RJ. Effect of nicardipine on rest and exercise hemodynamics in chronic congestive heart failure. Am J Cardiol. 1986;58:583-8. [PMID: 3751928] CrossrefMedlineGoogle Scholar 30. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S; The Adverse Experience Committee. Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52-60. [PMID: 1984898] CrossrefMedlineGoogle Scholar 31. Elkayam U, Weber L, McKay C, Rahimtoola S. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol. 1985;56:560-6. [PMID: 4036843] CrossrefMedlineGoogle Scholar 32. Kostis JB, Lacy CR, Cosgrove NM, Wilson AC. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J. 1997;133:550-7. [PMID: 9141377] CrossrefMedlineGoogle Scholar 33. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al ; Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-14. [PMID: 8813041] CrossrefMedlineGoogle Scholar 34. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al ; Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation. 1997;96:856-63. [PMID: 9264493] CrossrefMedlineGoogle Scholar 35. Levine TB, Bernink PJ, Caspi A, Elkayam U, Geltman EM, Greenberg B, et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. Circulation. 2000;101:758-64. [PMID: 10683349] CrossrefMedlineGoogle Scholar 36. Thackray S, Witte K, Clark AL, Cleland JG. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail. 2000;2:209-12. [PMID: 10856736] CrossrefMedlineGoogle Scholar 37. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized, controlled trials. JAMA. 1993;270:1589-95. [PMID: 8371471] CrossrefMedlineGoogle Scholar 38. Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation. 1993;88:2953-61. [PMID: 8252708] CrossrefMedlineGoogle Scholar 39. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, et al . Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996;93:1262-77. [PMID: 8653857] CrossrefMedlineGoogle Scholar 40. . Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-8. [PMID: 8782752] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of California, Los Angeles, Los Angeles, California.Grant Support: By a contract from Pfizer Inc. to RAND.Acknowledgments: The author thanks Cheryl Pegus, MD, and Michael Rich, MD, for review of an earlier version of the paper containing the full set of proposed quality indicators and Patricia Smith for technical assistance.Corresponding Author: Gregg C. Fonarow, MD, Division of Cardiology, University of California, Los Angeles, 47-123 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095-1679; e-mail, [email protected]ucla.edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoACOVE Quality Indicators Metrics Cited ByQuality of Care in Patients With Inflammatory Bowel DiseaseResultados tras la implementación de un programa de mejora de la calidad del contenido de los informes de alta hospitalaria en insuficiencia cardiacaQuality of Care of Hospitalized Internal Medicine Patients Bedspaced to Non-Internal Medicine Inpatient UnitsAge and Receipt of Guideline-Recommended Medications for Heart Failure: A Nationwide Study of VeteransPrise en charge de l’insuffisance cardiaque des sujets âgés vulnérablesQuality Indicators for the Care of Heart Failure in Vulnerable EldersPatients' Health Literacy and Experience With InstructionsLa calidad en cardiología. Desde la teoría a la aplicación prácticaIndicadores de calidad relacionados con el reingreso y la muerte precoces tras la hospitalización por insuficiencia cardíacaFunctional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failureImproving Medication Knowledge Among Older Adults With Heart Failure: A Patient-Centered Approach to Instruction DesignQuality Indicators for the Management of Medical Conditions in Nursing Home ResidentsThe Effectiveness of an Integrated Care Pathway for Inpatient Heart Failure Treatment: Results of a Trial in a Community HospitalDilated versus nondilated cardiomyopathy in the elderly population treated with guideline-based medical therapy for systolic chronic heart failureQuality Indicators for the Management of Medical Conditions in Nursing Home ResidentsQuality of care indicators for gout managementPatient-centered instructions for medications prescribed for the treatment of heart failureStandardization as a Mechanism to Improve Safety in Health CareImproving Comprehension of Medication Instructions in Older Adults with Heart Failure: A Patient-Centered Approach 16 October 2001Volume 135, Issue 8_Part_2Page: 694-702KeywordsACE inhibitorsAtrial fibrillationClinical trialsElderlyHeart failureLeft ventricular ejection fractionLongitudinal studiesMorbidityMortalityQuality indicators ePublished: 16 October 2001 Issue Published: 16 October 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...